We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Stryker (SYK) Right Now
Read MoreHide Full Article
Stryker Corporation (SYK - Free Report) is currently one of the top stocks in the medical devices space.
In the past year, Stryker’s shares have rallied 23.2%, compared with the industry’s return of 14.1% and the S&P 500’s 15.3%.
Over the past 90 days, the Zacks Consensus Estimate for earnings per share rose 0.6% to $1.60. The company has a Zacks Rank #2 (Buy), which indicates the possibility of outperformance in the near term.
The stock has a VGM Style Score of B, which buoys optimism. Notably, stocks with a Growth Style Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, outperform most stocks.
Let’s find out whether the recent positive trend can sustain the stock’s impressive performance in the long run.
Mako is Stryker’s robotic-arm Assisted surgery platform. In the last reported quarter, Mako robot installations totaled 35 globally, with 27 in the United States. Additionally, the company had its first robot sale in Japan, where the approval for Mako is expected by the end of 2018.
Moreover, Mako Total Knee procedures for 2017 were 15,778, with 20% more competitive surgeons using the Triathlon Total Knee implant for the first time. Stryker exited 2017 with 372 Mako robots installed in U.S. hospitals, representing 10% of its customer base.
Guidance Solid
Stryker expects net sales to be positively impacted by 1% in 2018, courtesy of favorable foreign exchange rates. Adjusted earnings for 2018 are expected in the range of $7.07-$7.17. For the first quarter of 2018, the earnings guidance is $1.57-$1.62.
The company anticipates organic sales growth in the range of 6-6.5% for 2018.
Management projects capital expenditures in the range of $550-$600 million compared with approximately $600 million in 2017.
Strategic Buyouts
Stryker’s acquisition strategy has helped the company gain traction. The recent buyout of Minnesota-based Entellus Medical, Inc. is likely to help physicians to conveniently perform a wide range of ENT procedures.
Recently, Stryker acquired VEXIM, which specializes in the development and sale of vertebral compression fracture solutions.
Other Key Picks
A few other top-ranked stocks in the broader medical space are Bio-Rad Laboratories, Inc. (BIO - Free Report) , Envision Healthcare Corporation and Integer Holdings Corporation (ITGR - Free Report) .
Envision Healthcare has an expected long-term growth rate of 13% and a Zacks Rank #1.
Integer Holdings has an expected long-term growth rate of 15% and a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Here's Why You Should Invest in Stryker (SYK) Right Now
Stryker Corporation (SYK - Free Report) is currently one of the top stocks in the medical devices space.
In the past year, Stryker’s shares have rallied 23.2%, compared with the industry’s return of 14.1% and the S&P 500’s 15.3%.
Over the past 90 days, the Zacks Consensus Estimate for earnings per share rose 0.6% to $1.60. The company has a Zacks Rank #2 (Buy), which indicates the possibility of outperformance in the near term.
The stock has a VGM Style Score of B, which buoys optimism. Notably, stocks with a Growth Style Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, outperform most stocks.
Let’s find out whether the recent positive trend can sustain the stock’s impressive performance in the long run.
Stryker Corporation Price and Consensus
Stryker Corporation Price and Consensus | Stryker Corporation Quote
What Makes It an Attractive Pick?
Promising Mako Platform
Mako is Stryker’s robotic-arm Assisted surgery platform. In the last reported quarter, Mako robot installations totaled 35 globally, with 27 in the United States. Additionally, the company had its first robot sale in Japan, where the approval for Mako is expected by the end of 2018.
Moreover, Mako Total Knee procedures for 2017 were 15,778, with 20% more competitive surgeons using the Triathlon Total Knee implant for the first time. Stryker exited 2017 with 372 Mako robots installed in U.S. hospitals, representing 10% of its customer base.
Guidance Solid
Stryker expects net sales to be positively impacted by 1% in 2018, courtesy of favorable foreign exchange rates.
Adjusted earnings for 2018 are expected in the range of $7.07-$7.17. For the first quarter of 2018, the earnings guidance is $1.57-$1.62.
The company anticipates organic sales growth in the range of 6-6.5% for 2018.
Management projects capital expenditures in the range of $550-$600 million compared with approximately $600 million in 2017.
Strategic Buyouts
Stryker’s acquisition strategy has helped the company gain traction. The recent buyout of Minnesota-based Entellus Medical, Inc. is likely to help physicians to conveniently perform a wide range of ENT procedures.
Recently, Stryker acquired VEXIM, which specializes in the development and sale of vertebral compression fracture solutions.
Other Key Picks
A few other top-ranked stocks in the broader medical space are Bio-Rad Laboratories, Inc. (BIO - Free Report) , Envision Healthcare Corporation and Integer Holdings Corporation (ITGR - Free Report) .
Bio-Rad has an expected long-term growth rate of 20% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Envision Healthcare has an expected long-term growth rate of 13% and a Zacks Rank #1.
Integer Holdings has an expected long-term growth rate of 15% and a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>